Intellectual Property

Phylogica has a strong intellectual property portfolio around its proprietary Phylomer^® peptide library and associated technology.

Phylogica has over 16 patent families comprising multiple granted/allowed patents covering international markets, including the US, and Australia. Phylomer^® peptides, being fragments of naturally occurring proteins sourced from the genomes of an evolutionary diverse range of microbes (Bacteria and Archaea) and therefore have a different origin than antibodies and hence are not bound by traditional antibody patents.

Phylogica’s patent families cover methods of making the Phylomer^® libraries, methods of screening them and composition-of-matter claims for Phylomer^® libraries and individual Phylomer^® peptides discovered for therapeutic and diagnostic applications.